Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Business https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Coty, Skyworks, Wynn Resorts and more

Coty, Skyworks, Wynn Resorts and more

Check out the companies that make headlines in the dinner trade:

Chip stocks – Shares of chipmaker stocks rose broadly after President Donald Trump and Chinese President Xi Jinping agreed not to impose new rates on US and Chinese goods and Trump said that China will ease its ban on US companies selling products to Huawei. Skyworks rose 6%, Western Digital rose 4%, Micron rose 3%, Qualcomm rose 1%, Broadcom 4% and AMD rose 2% and Nvidia increased 1%.

Coty- Shares of Cosmetic Distributor Coty fell 13% after the company revealed its restructuring plan, which includes spending $ 600 million over the next four years to "rediscover growth" and improve margins, the company said in a release. Coty, which distributes cosmetic brands such as Opi, Covergirl and Sally Hansen, was the best possible share in S & P 500 in the first half of 201

9 and wins more than 100%.

Wynn Resorts, Las Vegas Sands Stocks of Casino Stocks Wynn Resorts and Las Vegas Sands rose 5% and 4% respectively after Macau gaming authority said the gaming revenue was better than expected in June. Gross gaming revenue in Macau increased 5.9% last month, while StreetAccount estimates a 2.5% increase.

MSG Networks – The cable network holding fell 1.9% after failing to sign NBA Kevin Durant and other superstar free agents. The company that sends New York Knicks will miss higher viewers and increased revenue. At the warehouse's lowest day, down 8.1%, MSG Networks had lost $ 126 million in market value. More than half of the $ 164 million reported by ESPN Brooklyn Nets will pay to sign Durant for a four-year contract.

Biogen Biogen shares increased 0.7% after the biotech company reported positive results for its spinal muscle atrophy drug Spinraza. The company cited "unprecedented" results, including that 88% of pre-symptomatic children treated with the drug were able to go independently.

United Therapeutics-United Therapeutics shares rose 5% after Credit Suisse upgraded the biotech company to transition from neutral and raised its target price to $ 101 from $ 98 per share. Credit Suisse said the company's valuation is attractive at the current level.

Evo Payments-Evo-Payment Shares fell 6% after BTIG downgraded the payer to neutral from purchase. BTIG quoted a full valuation after the share's 27% increase this year.

CNBC's Marc Rod, Mallika Mitra and Elizabeth Myong contributed to this report.

Source link